Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

Authors
Type
Published Article
Journal
Cancer
1097-0142
Publisher
Wiley Blackwell (John Wiley & Sons)
Publication Date
Volume
119
Issue
24
Pages
4284–4289
Identifiers
DOI: 10.1002/cncr.28328
PMID: 24105694
Source
Medline
Keywords
License
Unknown

Abstract

The results of the current study demonstrate that in combination with imatinib, the efficient dose of PegIFNa2a appears to be 45 μg/week. Society.

Statistics

Seen <100 times